

CONTACT

Paul, Weiss, Rifkind,
Wharton & Garrison LLP

Brad S. Karp
Chairman
212-373-3316
bkarp@paulweiss.com

Laura Van Drie
Communications Director
212-373-2131
lvandrie@paulweiss.com

New York
Brussels
Hong Kong
London
Los Angeles
San Francisco
Tokyo
Toronto
Washington, D.C.
Wilmington

FOR IMMEDIATE RELEASE

Paul, Weiss Adds Leading Life Sciences Partner in New York

New York, March 17, 2025 – Paul, Weiss, Rifkind, Wharton & Garrison LLP announced today that Jeffrey Osterman has joined the firm as chair of Life Sciences Licensing & Collaboration Transactions and an IP & Technology Transactions partner in the Corporate Department, resident in New York. Osterman brings significant experience in the life sciences sector, advising clients on transactions from drug discovery to commercialization, joint ventures and high-value acquisitions.

“Jeff is widely regarded as one of the nation’s top advisors to life sciences and technology companies, and we are thrilled that he is joining our partnership,” said Paul, Weiss Chairman Brad S. Karp. “His extensive experience counseling on complex transactions, including cutting-edge life science technologies, will allow us to continue to offer our clients the innovative, effective solutions they have come to rely on us for.”

“Jeff is an excellent addition to our IP & Technology Transactions group,” said Krishna Veeraraghavan, global co-head of the firm’s Mergers & Acquisitions Group. “Life sciences deals often depend on the strategic management of technology and IP assets, and Jeff is among the best in the area.”

Osterman has long advised major pharmaceutical companies on a variety of commercial IP matters, licensing and collaboration agreements, and manufacturing and supply arrangements. He has been involved in various transactions involving novel therapeutic modalities, including genetic medicine and AI-assisted target and drug discovery, while also leading technology and intellectual property aspects of major corporate transactions and their associated commercial arrangements. He also advises on the treatment of intellectual property matters in bankruptcy cases. Osterman’s recent representations include, among others, Eli Lilly in various transactions, including its acquisition of Loxo Oncology, Inc., the separation of its Elanco Animal Health business, and collaboration and license agreements with numerous companies; and Sanofi in its acquisitions of Amunix Pharmaceuticals and Ablynx. Osterman also has substantial experience in transactions outside the life

sciences industry, including representing Lehman Brothers and General Motors on intellectual property matters associated with their bankruptcy cases.

Osterman has been recognized for more than a decade as a leading lawyer by *Chambers USA* and *The Legal 500 US*, as well as in *IAM Global Leaders*, *IAM Patent 1000*, *Managing Intellectual Property* and *Lawdragon*.

“I am excited to join Paul, Weiss and collaborate with such a talented team,” said Osterman. “I look forward to delivering innovative solutions for our clients, especially in the rapidly evolving life sciences and technology industries.”

Osterman earned his B.A. from Cornell University and his J.D. from Harvard Law School, where he graduated *cum laude*. He is admitted to practice in New York.

About Paul, Weiss

Paul, Weiss, Rifkind, Wharton & Garrison LLP is a premier firm of more than 1,000 lawyers with diverse backgrounds, personalities, ideas and interests who provide innovative and effective solutions to our clients' most complex legal and business challenges. The firm represents many of the world's largest and most important public and private corporations, asset managers and financial institutions, as well as clients in need of pro bono assistance.